Cited by 443Genomics and Chromatin DynamicsHemoglobinopathies and Related DisordersHemoglobin structure and function

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; none of the 33 sources its claims cite is checked for support yet.

Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping

Open access

Abstract

Distal enhancers commonly contact target promoters via chromatin looping. In erythroid cells, the locus control region (LCR) contacts β-type globin genes in a developmental stage-specific manner to stimulate transcription. Previously, we induced LCR-promoter looping by tethering the self-association domain (SA) of Ldb1 to the β-globin promoter via artificial zinc fingers. Here, we show that targeting the SA to a developmentally silenced embryonic globin gene in adult murine erythroblasts triggers its transcriptional reactivation. This activity depends on the LCR, consistent with an LCR-promoter looping mechanism. Strikingly, targeting the SA to the fetal γ-globin promoter in primary adult human erythroblasts increases γ-globin promoter-LCR contacts, stimulating transcription to approximately 85% of total β-globin synthesis, with a reciprocal reduction in adult β-globin expression. Our findings demonstrate that forced chromatin looping can override a stringent developmental gene expression program and suggest a novel approach to control the balance of globin gene transcription for therapeutic applications.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Forced chromatin looping by tethering the Ldb1 self-association domain to developmentally silenced globin promoters reactivated embryonic/fetal globin expression in adult erythroid cells. In human adult erythroblasts, targeting the γ-globin promoters raised γ-globin to ~85% of total β-globin synthesis and reduced adult β-globin expression.

Key findings

  • Tethering Ldb1 SA to the murine embryonic βh1-globin promoter activated βh1-globin transcription: 368-fold in G1E cells, 26-fold in GATA1-replete cells (~15% of total β-globin), and almost 800-fold in primary adult murine erythroblasts (>30% of total β-globin synthesis).
  • βh1-SA activation required the LCR: induction was completely abrogated in erythroid cells from ΔLCR mice, while basal βh1 transcription was unaffected.
  • In primary adult human erythroblasts, GG1-SA targeting γ-globin promoters increased γ-globin to ~85% of total globin synthesis versus ~25% in controls, with a ~2.5-fold increase normalized to α-globin and reduced β-globin transcription (13.5% vs. control; 18.1% vs. GG1-Only).
  • 3C showed GG1-SA increased LCR–γ-globin contacts and decreased LCR–adult β-globin contacts, supporting a competitive looping mechanism; HPLC also showed increased HbF and reduced HbA/HbA2.

Methods

  • Artificial zinc finger proteins were fused to the Ldb1 SA domain and introduced by retroviral or lentiviral infection into G1E murine erythroblasts, primary murine E13.5 fetal liver erythroblasts (wild-type or ΔLCR/ΔLCR), K562 cells, and primary human CD34+ cells from bone marrow or peripheral blood differentiated toward erythroid lineage.
  • Binding and expression were assessed by ChIP, RT-qPCR, flow cytometry/immunostaining, HPLC for hemoglobins, and chromosome conformation capture (3C).
  • Key genetic test used erythroid cells from mice lacking the LCR to determine whether βh1-SA activity depended on long-range LCR action.

Limitations

  • The paper states that 3C for βh1-globin in G1E cells was not reliable because of high basal signals and insufficient signal-to-noise, so LCR dependence was tested genetically with ΔLCR mice instead.
  • The paper notes donor variation in basal γ-globin expression (<10% to 50% of total globin synthesis) and sizeable error bars in 3C, requiring normalization and individual-sample plotting.
  • The paper states that βh1-SA impaired expression of a few erythroid genes (Band3, AHSP, Alas2) in murine cells, likely via dominant-negative effects at high expression; human SA-fusion proteins did not inhibit orthologous genes. Evident from the text: the therapeutic strategy was tested in cultured primary cells, not in patients or in vivo disease models, and the paper notes that strengths and weaknesses must be considered before human use.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2014.05.050

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 33 cited sources checked · 0 supported · 0 flagged

  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 9
23 of 23
  • The paper relies on this without support.

    As erythroid cells undergo maturation, the ratio of fetal to adult hemoglobin declines.

    “As erythroid cells undergo maturation, the ratio of fetal to adult hemoglobin declines.”
  • The paper relies on this without support.

    In normal adults, total fetal hemoglobin synthesis ranges below 3% but is concentrated in a small fraction of cells with high fetal hemoglobin expression (F-cells).

    “Second, in normal adults, total fetal hemoglobin synthesis ranges below 3% but is concentrated in a small fraction of cells with high fetal hemoglobin expression (F-cells).”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 55 references

1 of the 55 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 443

Metadata

Authors
Deng, W., Rupon, J. W., Krivega, I., Breda, L., Motta, I., Jahn, K. S., Reik, A., Gregory, P. D., Rivella, S., Dean, A., & Blobel, G. A.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • National Institutes of Health (US)
  • Weill Cornell Medicine (US)
  • Sangamo BioSciences (United States) (US)
Corresponding author
Blobel, Gerd A.
Venue
Cell
Publisher
Elsevier BV
Published
2014-08
Volume
158
Issue
4
Pages
849-860
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2121659981
Cited by
443
References
55
Citations by year
2026: 15 · 2025: 28 · 2024: 21 · 2023: 29 · 2022: 25 · 2021: 43 · 2020: 36 · 2019: 43 · 2018: 60 · 2017: 55 · 2016: 45 · 2015: 38 · 2014: 4
FWCI
19.42
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (1RO1HL119479, 5R37DK058044)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK015508)
  • American Heart Association (13POST16950014)
  • Associazione Italiana per la Lotta al Neuroblastoma (FP7-HEALTH-2012-INNOVATION, NHLBI-5R01HL102449)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
Keywords
chromatin looping, locus control region, beta-globin gene, embryonic globin, transcriptional reactivation, erythroid cells, gene silencing, globin gene regulation, erythroblasts
MeSH terms
Animals, Chromatin, Embryo, Mammalian, Erythroblasts, Fetal Hemoglobin, Genetic Techniques, Hemoglobinopathies, Humans, Transcriptional Activation, Antigens, CD34, Locus Control Region, Mice, beta-Globins, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review